Hailing Liu

300 Guangzhou Road, Jiangsu
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Circulating NK-cell counts improve prognostic stratification of the PINKE model in extranodal NK/T-cell lymphoma: a retrospective cohort study.

Circulating NK-cell counts improve prognostic stratification of the PINKE model in extranodal NK/T-cell lymphoma: a retrospective cohort study.

Journal: Leukemia research
Published: May 08, 2026

Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.

Survival Outcomes and Prognostic Factors in Patients With Primary Central Nervous System Low-Grade B-Cell Lymphoma: A Population-Based Cohort Study.

Journal: Cancer medicine
Published: May 07, 2026

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia.

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia.

Journal: Annals of medicine
Published: March 09, 2026

Dual resistance to asparaginase and PD-1 blockade in extranodal natural killer/T-cell lymphoma: dismal outcomes from a multicenter cohort.

Dual resistance to asparaginase and PD-1 blockade in extranodal natural killer/T-cell lymphoma: dismal outcomes from a multicenter cohort.

Journal: Haematologica
Published: February 03, 2026

Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL.

Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL.

Journal: Annals of hematology
Published: January 20, 2026

Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial.

Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial.

Journal: Leukemia
Published: December 25, 2025

Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.

Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.

Journal: British journal of haematology
Published: November 10, 2025

Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient Multicenter Cohort.

Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient Multicenter Cohort.

Journal: American journal of hematology
Published: October 07, 2025

Limited Benefit of Bone Marrow Biopsy in Extranodal NK/T-Cell Lymphoma in the PET/CT Era.

Limited Benefit of Bone Marrow Biopsy in Extranodal NK/T-Cell Lymphoma in the PET/CT Era.

Journal: Academic radiology
Published: August 11, 2025

Progression of disease within 6 months: revised early disease progression threshold for ENKTL.

Progression of disease within 6 months: revised early disease progression threshold for ENKTL.

Journal: Leukemia & lymphoma
Published: June 11, 2025

CD96 as a therapeutic target for CAR T cell therapy in acute myeloid leukemia.

CD96 as a therapeutic target for CAR T cell therapy in acute myeloid leukemia.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 14, 2025

Mass transfer and multi-phase fluid flow in electro-coagulation: A review.

Mass transfer and multi-phase fluid flow in electro-coagulation: A review.

Journal: Water research
Published: February 13, 2025
Showing 1-12 of 29

Last Updated: 09/26/2026